Digestive toxicity of low-dose aspirin: An underestimated and unresolved problem;Toxicité digestive de l'aspirine à faible dose: Un probléme sous-estimé et non résolu

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 3, 2001, Pages 229-232

  Thiefin G ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; OMEPRAZOLE;

CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG USE; EDITORIAL; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS;

ASPIRIN; CARDIOVASCULAR DISEASES; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0034995527     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (39)

1. Platelet-active drugs. The relationships among dose, effectiveness, and side effects
2. Prophylactic aspirin and risk of peptic ulcer bleeding
3. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric or buffered product
4. Hémorragies digestives hautes et aspirine à faible dose
5. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke
6. European Stroke Prevention Study. II - Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
7. Dose-effects of aspirin on gastric prostaglandins and stomach mucosal injury
8. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans
9. Human gastric mucosal bleeding induced by low dose aspirine, but not warfarin
10. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin. Analysis of gastrointestinal bleeding during the UK-TIA trial
11. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
12. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events
13. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs and the risk of upper gastrointestinal bleeding
14. Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
15. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
16. Reversible prolonged skin bleeding timle in acute gastrointestinal bleeding presumed due to NSAIDs
17. Aspirin-related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use
18. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
19. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs
20. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
21. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: Combination therapy with antisecretory agents in rats
22. Omeprazole does not interfere with the antiplatelet effect fo low-dose aspirin in man
23. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: A three-way debate
24. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen
25. Helicobacter pylori and nonsteroidal anti-inflammatory drugs: Interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications. Future research needs
26. Regulation of gastric mucosal integrity by endogenous nitric oxide: Interactions with prostanoids and sensory neuropeptides in the rat
27. Biosynthesis and role of endothelium-derived vasodilator, nitric oxide, in the gastric mucosa
28. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach
29. Novel nonsteroidal antiinflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat
30. A nitric oxide-releasing nonsteroidal antiinflammatory drug accelerates gastric ulcer healing in rats
31. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative
32. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016
33. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats
34. Nitric oxide donating flurbiprofen (HCT 1026) causes less endoscopic damage in healthy volunteers than flurbiprofen
35. Gastric mucosal barrier: Hydrophobic lining to the lumen of the stomach
36. Gastric surfactant and the hydrophobic mucosal barrier
37. Phospholipid- and neutral lipid-containing organelles of rat gastro-duodenal mucous cells. Possible origin of the hydrophobic mucosal lining
38. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced injury
39. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects